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INTRODUCTION 
"Man may be the captain of his fate, but he is also the 
victim of his blood sugar" said by Dr. Wilfred Oakley 
1
.  
The prevalence of diabetes in 21
st
 century is increasing 
due to diet changes, aging, urbanization, and increasing 
prevalence of obesity and physical inactivity. King et 
al., 1998 predicted a rise in global diabetes prevalence 
to 5.4% of the world population by the year 2025 (27% 
increase in developed countries and 48% increase in 
developing countries) 
2
. In 2000, there were 171 
millions of people having diabetes in the world; 2006 
was 246 million people. It was estimated that in 2025, 
there would be 380-399 million people having diabetes 
3
. According to an estimate of International Diabetes 
Federation comparative prevalence of Diabetes during 
2007 is 8.0 % and likely to increase to 7.3% by 2025. 
Number of people with diabetes is 246 million (with 
46% of all those affected in the 40–59 age group) and 
likely to increase to 380 million by 2025 
4
. The World 
Health Organization believes that the 21
st
 century is the 
time of endocrine diseases and metabolic disorders, for 
example, diabetes. In over the world, people have to 
spend 232 billion to 430 billion USD for diabetes 
treatments and prevention. Diabetes reduces 5-10 years 
of human life expectancy. In 2014, the World Health 
Organization indicates global prevalence of diabetes 
was estimated to be 9% among adults aged 18+ years 
and it will be the 7th leading cause of death in 2030 
5-7
.  
Diabetes is a metabolic disorder caused by many 
reasons. It is characterized by chronic hyperglycemia 
and metabolic disorders of sugar, protein, fat caused by 
the deficiency of insulin secretion, the insulin 
activities, or both. Pathophysiology of type 2 and 1 
Diabetes Mellitus is explained in the Fig. 1 and Fig. 2 
respectively 
8
. 
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ABSTRACT 
Diabetes mellitus (DM) is a group of metabolic disorders characterized by a chronic hyperglycemic condition resulting from 
defects in insulin secretion, insulin action or both. The prevalence of diabetes is increasing rapidly worldwide and the World 
Health Organization indicates global prevalence of diabetes was estimated to be 9% among adults aged 18+ years and it will 
be the 7th leading cause of death in 2030. The aim of this paper is to gather latest information on the prevalence of Diabetes 
among the human society and also to investigate pharmaceutical marketing of Metformin and its combinations used for 
Diabetes Mellitus in various districts of U.P. (West) region. The survey was based on the questionnaire which was presented 
before the physicians and the pharmacist in-charge on medical store to get information about the patient having diabetes 
mellitus and commonly prescribed brands of Metformin alone and its combination with other anti-diabetic drugs. On the 
basis of physician’s opinion on the Diabetes (type 2), 65.78% of patients from total OPD patients was found to have 
diabetes,  49.76% patients are type-2 patients, 7.45% of teenagers was fall in the category of having type-1 diabetes and 
8.57% were among the new patients of diabetes. There are 20 and 30 brands in Metformin (and its HCl salt), Metformin 
(and its HCl salt) with other anti-diabetic drug categories, respectively. The sale of Glyciphage of Franco Indian Remedies 
brand of the Metformin only, Diapride M 1 containing Glimepiride and Metformin 500 mg from Micro Labs Ltd., 
respective categories, were highest in the area of interest. 
Keywords: Diabetes Mellitus, Metformin (and its HCl salt), Combination drugs, Marketing Investigation. 
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Figure 1: Pathophysiology of Type 2 Diabetes Mellitus 
 
Pharmaceutical marketing, sometimes called medico-marketing or pharma marketing 
in some countries is the business of advertising or otherwise promoting the sale of 
pharmaceuticals or drugs [9]. Pharmaceutical detailing is a marketing technique used 
by pharmaceutical companies to educate a physician about a vendor's products in 
hopes that the physician will prescribe the company’s products more often. Although 
this practice is controversial, many drug companies spend billions of dollars a year on 
this legal tactic. In the United States, marketing and distribution of pharmaceuticals is 
regulated by the Federal Food, Drug, and Cosmetic Act and the Prescription Drug 
Marketing Act, respectively. Food and Drug Administration (FDA) regulations 
require all prescription drug promotion to be truthful and not misleading, based on 
"substantial evidence or substantial clinical experience", to provide a "fair balance" 
between the risks and benefits of the promoted drug, and to maintain consistency with 
labeling approved by the FDA. The FDA Office of Prescription Drug Promotion 
enforces these requirements 
9
.  
 
 
Figure 2: Pathophysiology of Type 1 Diabetes Mellitus 
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It  was  long believed  that  since  physicians  made  the 
selection  of  drugs,  mass  marketing  was  a waste  of  
resources;  specific  advertisement targeting the 
medical profession were thought to be cheaper and just 
as effective. This would involve  advertisement  in  
professional  journals and  visits  by  sales  staff  to  
physician’s  offices and  hospitals.  An important part 
of these efforts was marketing to medical students 
10
. 
On the basis of this background, we made 
pharmaceutical marketing investigation of Metformin 
and  its combinations  used  for  Diabetes  Mellitus  in 
Moradabad, Rampur, Bareilly and Meerut districts of 
U.P. (West). 
Pharmaceutical marketing, sometimes called medico-
marketing or pharma marketing in some countries is the 
business of advertising or otherwise promoting the sale 
of pharmaceuticals or drugs [9]. Pharmaceutical 
detailing is a marketing technique used by 
pharmaceutical companies to educate a physician about 
a vendor's products in hopes that the physician will 
prescribe the company’s products more often. Although 
this practice is controversial, many drug companies 
spend billions of dollars a year on this legal tactic. In 
the United States, marketing and distribution of 
pharmaceuticals is regulated by the Federal Food, 
Drug, and Cosmetic Act and the Prescription Drug 
Marketing Act, respectively. Food and Drug 
Administration (FDA) regulations require all 
prescription drug promotion to be truthful and not 
misleading, based on "substantial evidence or 
substantial clinical experience", to provide a "fair 
balance" between the risks and benefits of the promoted 
drug, and to maintain consistency with labeling 
approved by the FDA. The FDA Office of Prescription 
Drug Promotion enforces these requirements 
9
.  
It  was  long believed  that  since  physicians  made  the 
selection  of  drugs,  mass  marketing  was  a waste  of  
resources;  specific  advertisement targeting the 
medical profession were thought to be cheaper and just 
as effective. This would involve  advertisement  in  
professional  journals and  visits  by  sales  staff  to  
physician’s  offices and  hospitals.  An important part 
of these efforts was marketing to medical students 
10
. 
On the basis of this background, we made 
pharmaceutical marketing investigation of Metformin 
and  its combinations  used  for  Diabetes  Mellitus  in 
Moradabad, Rampur, Bareilly and Meerut districts of 
U.P. (West). 
MATERIALS AND METHODS 
This  study  was depended on  a cross-sectional  survey 
design  and  was  conducted  by  administering  a 
validated  questionnaire  to  physicians  and pharmacist 
on medical  store  of  Moradabad, Rampur, Bareilly and 
Meerut districts of U.P. (West) on  metformin  and  its  
combination drugs.  Since  this  study  was  carried  out  
during April 2015- April 2016,  the  sample size 
consisted of 10 Physicians  and  10 pharmacist in-
charge of medical store in the districts (Moradabad, 
Rampur, Bareilly, Meerut) of U.P.(West) region which 
will tend to reflect the population size. Both physician 
as well as pharmacist was informed with the objectives 
of the study, and they were considered consented to 
participate in the survey. 
Study Instrument: 
A questionnaire (Table 1) was designed to collect 
information on Diabetes mellitus from the physicians. 
Another questionnaire (Table 2) was prepared for 
collecting information from pharmacists on medical 
stores. Both questionnaires were initially validated by 
two senior faculty members for content before data 
collection. 
RESULTS AND DISCUSSION 
Physician Opinion: 
The objective of the study was to conduct and analyze a 
survey regarding the status of diabetes mellitus-2 
among the people of various districts of U.P. west 
region of India. 
Being diagnosed with diabetes is a major life stress and 
therefore it requires dealing with psychological 
challenges (grief, denial, anxiety, depression, shame 
and guilt). Various aspects of life associated diabetes 
that may affect quality of life include:  
 The never-ending demands of diabetes care, such 
as eating carefully, exercising, monitoring blood 
glucose, and scheduling and planning 
 Symptoms of low or very high blood glucose 
 Fears about or the reality of complications 
The specific things each person needs to feel satisfied 
and happy are unique to him or her. Still, there are 
some things most people would agree are important. 
Your quality of life is your own sense of how satisfied 
and happy you are with your life in general and your 
life with diabetes in particular. Many diabetes health 
care professionals are trained to help their patients 
adjust treatment regimens to ease the burden of 
diabetes management while maintaining good blood 
glucose control and good health. These providers may 
also be able to help you improve your day-to-day 
diabetes coping skills. 
The data obtained after conducting the survey was 
drastically modified in comparison to the survey 
reported by Phool et al., (2013) 
11
. In 2013, there were 
around 46.48% patients having diabetes and in 2015 
the numbers are increased to 65.78%. The major 
outcome was found among the teenagers, 7.45% of 
teenagers are having type-1 diabetes. After consulting 
with the medical practitioner, the sole reason of having 
these disorders was found to be the improper nutritious 
diet taking and the magnetic effect of junk food, no 
physical exercise, increased mental stress, 
environmental toxins, etc, all these factors directly or 
indirectly linked to insulin resistance (a condition in 
which the body’s muscle, fat, and liver cells do not use 
insulin effectively to counter the raised blood glucose 
level and resulted into diabetes). 
Physician opinions on the questionnaire about the 
Diabetes (type-1 & -2) are shown in the Fig. 3. 65.78% 
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of patients from total OPD patients were found to have 
diabetes, 49.76% patients are type-2 patients, 7.45% of 
teenagers were fall in the category of having type-1 
diabetes and 8.57% were among the new patients of 
diabetes. Among various anti-diabetic drugs, 
Metformin, an oral antidiabetic drug in the biguanide 
class is the first-line drug of choice for the treatment of 
type-2 diabetes in particular, in overweight and obese 
people and those with normal kidney function, while 
Insulin become the primary drug of choice for type-1 
Diabetic patients. 
 
 
Figure 3: Physicians opinion on different type of patients 
Pharmacist in-charge report: 
There are 20 brands containing Metformin and its 
Hydrochloride salt found majorly in the market are 
mentioned in appendix 2 (Table 2). The sale of 
Glyciphage of Franco Indian Remedies brand 
containing Metformin only was higher among all other 
medicine and the sale was 22% of the total market and 
results are shown in the Fig. 4. Apart from the only 
metformin brand there are 30 brands of metformin (& 
its HCl salt) in combination with other anti-diabetics 
drugs found majorly in the market are listed in 
Appendix 3 (Table 3). The investigation results 
produced the highest sale of Diapride M 1 containing 
Glimepiride and Metformin of Micro Labs Ltd. The 
sale was 35% and presented in Fig. 5. None of the 
pharmacist was agreed to sell metformin without 
prescription of physician. This reveals the great 
collaboration of pharmacist and physician to follow the 
rules laid by the FDA and the Central Government. 
 
 
Figure 4: Pharmacist in-charge report on branded products of Metformin only 
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Table 1: Questionnaire for the physician 
APPENDIX 1 
PHARMACEUTICAL MARKETING REPORT: 
“Physician  opinion  on  diabetes  Mellitus  and  Metformin and  its 
Combinations” 
1 How many patients are coming to OPD in a day? 
2 How many patients are suffering from Diabetes Mellitus? 
3 How many patients are suffering from Type-2 Diabetes? 
4 How many of them are new patients? 
5 What is your choice of drug to treat type-2 Diabetes? 
6 What are the concerns associated with Diabetes in your practice regarding quality of life? 
7 What are the psychological impacts of diabetes on the life of diabetic patient? 
8 Do you prescribe Metformin and its combinations? 
9 If yes, then what are their brand names? 
10 Do you prescribe generics over branded drugs? 
                                                                                                                                      Sign & Seal 
 
Table 2: Report from Pharmacist in-charge on brands having only metformin 
APPENDIX 2 
PHARMACEUTICAL MARKETING REPORT: 
Pharmacist in-charge report about the Metformin and its combinations 
(Brands having only Metformin) 
S.No. Brand Company Strength 
1 Bigesens Zydus Cadila Healthcare Ltd 500 mg, 1000 mg 
2 Cetapin Sanofi Aventis 500mg 
3 Duomet ER Biochem Pharmaceutical Industrial Ltd 500 mg 
4 Emnorm IPCA Laboratories Ltd 250 mg, 500 mg, 850 mg 
5 Exermet Cipla Limited 500 mg 
6 Formet Alkem Laboratories Ltd 850 mg 
7 Formin Alkem Laboratories Ltd 500 mg 
8 Forminal, Forminal SR Alembic Chemical Works Co Ltd 500 mg, 850 mg, 1000 mg 
9 Glumet, Glumet EXT Cipla Limited 500 mg, 850 mg 
10 Glyciphage, Glyciphage SR Franco Indian Remedies 250 mg, 500 mg 
11 Glyrep, Glyrep XL Emcure Pharmaceuticals Ltd. 500 mg, 1000 mg 
12 Insumet, Insumet SR Cadila Pharmaceuticals Ltd. 500 mg, 850 mg 
13 Melmet, Melmet SR DTF (Micro Labs Ltd) 500 mg 
14 Metica Sarabhai Piramal Pharmaceutical Ltd 500 mg, 850 mg 
15 Metlife - 500 Mankind Pharmaceuticals Pvt. Ltd 500 mg 
16 Metlong -DS Panacea Biotec Ltd 500 mg 
17 Metsar SR Unichem Laboratories Ltd. 500 mg 
18 Obimet Abbott India Ltd 500 mg 
19 Okamet Cipla Limited 500 mg 
20 Zomet, Zomet SR Piramal Healthcare 500 mg 
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Figure 5: Pharmacist in-charge report on branded products of Metformin and its combinations. 
Table 3: Report from Pharmacist in-charge on brands having only metformin and its combination 
APPENDIX 3 
PHARMACEUTICAL MARKETING REPORT: 
Pharmacist in-charge report about the Metformin and its combinations 
(Brands having only Metformin and its combination) 
S.No Brand Combination strength Company 
1 Glimulin-MF Glimepiride 1 mg, Metformin 500 mg- SR Glenmark 
2 Glimulin-MF Forte Glimepiride 2 mg, Metformin HCl (SR) 500 mg Glenmark 
3 Glinate-MF Nateglinide 60 mg, Metformin 500 mg Glenmark 
4 Amaryl-M Glimepiride 1mg, Metformin XR 500mg Sanofi Aventis 
5 Amaryl-M 2 Glimepiride 2mg, Metformin (XR) 500mg Sanofi Aventis 
6 Amaryl-M Forte Glimepiride 1mg, Metformin 1000mg Sanofi Aventis 
7 Amaryl-M Forte Glimepiride 2 mg, Metformin 1000 mg Sanofi Aventis 
8 Diapride-M 1 Glimepiride 1 mg, Metformin 500 mg Micro Labs Ltd 
9 Azukon-M Gliclazide 80mg, Metformin HCl 500 mg Torrent 
10 Azulix-MF Glimepiride 1mg, Metformin HCI 500 mg Torrent 
11 Azulix-MF Glimepiride 2mg, Metformin HCI 500 mg Torrent 
12 Azulix-MF Forte Glimepiride 1mg, Metformin HCI 1000 mg Torrent 
13 Azulix-MF Forte Glimepiride 2mg, Metformin HCI 1000 mg Torrent 
14 Betaglim-M1 Glimepiride 1mg, Metformin HCI (in Extended release form) 500 mg Panacea 
15 Betaglim-M2 Glimepiride 2mg, Metformin HCI (in Extended release form) 500 mg Panacea 
16 Betagrim-M Glimepiride 1 mg, Metformin 500 mg Panacea 
17 Betagrim-M Glimepiride 2 mg, Metformin 500 mg Panacea 
18 Daonil-M Glibenclamide 5mg, Metformin (XR) 500mg Sanofi Aventis 
19 Daorid-M Glibenclamide 5 mg, metformin 500 mg Intas 
20 Diaglip-M Glipizide 5mg, Metformin 500 mg Cipla 
21 Diatrol-M Gliclazide 80mg, Metformin 500 mg Aurobindo 
22 Dibimet Plus Glipizide 5mg, Metformin HCI 500 mg Novartis 
23 Geminor-M Glimepiride 1 mg, Metformin 500 mg Macleods 
24 Glimy-M Glimepiride 2 mg, Metformin HCl 500 mg Dr. Reddy's 
25 Janumet Metformin HCl 500 mg, Sitagliptin 50 mg Merck 
26 Glucobay M25 Acarbose 25 mg, Metformin HCl 500 mg Bayer 
27 Glucobay M50 Acarbose 50 mg, Metformin HCl 500 mg Bayer 
28 Galvumet Vildagliptin 50 mg, Metformin HCl 1000 mg Novartis 
29 Vogli M 0.2 Voglibose 0.2 mg, Metformin HCl 500 mg Medley Pharm. 
ltd 
30 Vogli GM 2 Voglibose 0.3 mg, Metformin HCl 500 mg, Glimepiride 2 mg Medley Pharm 
ltd 
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STUDY LIMITATION 
The study gives an idea about the collaboration of 
Doctor-pharmacist. However, it has some limitations. 
The sample size is small which provides a brief idea. To 
increase precision, the sample size may be increased. 
CONCLUSION 
The global burden of diabetes is increasing worldwide 
as it is a costly disease for developing economies of the 
world. While many pharmaceutical companies have 
successfully deployed a plethora of strategies to target 
the various customer types, recent business and 
customer trends are creating new challenges and 
opportunities for increasing profitability. In the 
pharmaceutical and healthcare industries, a complex 
web of decision-makers determines the nature of the 
transaction (prescription) for which direct customer of 
pharma industry (doctor) is responsible. Essentially, the 
end-user (patient) consumes a product and pays the cost. 
During the process of task we have extracted out that 
Diabetes Mellitus found to be an epidemic disease 
among the population of India. Glyciphage, Melmet 
And Obimet were the brands of the Metformin only, 
Metformin: Glimepiride, Metformin: Glimepiride: 
Voglibose and Metformin: Gliclazide, respectively 
categories which were in highest sale in the area of 
interest. 
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